tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
US Market
DAWN
Day One Biopharmaceuticals
RESEARCH TOOLSreports

Day One Biopharmaceuticals (DAWN) Stock News & Sentiment

Compare
395 Followers
Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial
Premium
Ratings
Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial
19d ago
DAWN
Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
Premium
Company Announcements
Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
20d ago
8K
DAWN
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
Premium
Ratings
Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
20d ago
DAWN
Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals’ Ojemda
Premium
Ratings
Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals’ Ojemda
20d ago
DAWN
Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals’ Market Potential: Buy Rating Affirmed
Premium
Ratings
Strategic Acquisition of Mersana Therapeutics Boosts Day One Biopharmaceuticals’ Market Potential: Buy Rating Affirmed
30d ago
DAWN
Strategic Acquisition and Promising Drug Pipeline Drive Buy Rating for Day One Biopharmaceuticals
Premium
Ratings
Strategic Acquisition and Promising Drug Pipeline Drive Buy Rating for Day One Biopharmaceuticals
1M ago
DAWN
Strategic Acquisition of Mersana by Day One: Enhancing Pipeline and Growth Prospects
Premium
Ratings
Strategic Acquisition of Mersana by Day One: Enhancing Pipeline and Growth Prospects
1M ago
DAWN
More DAWN News >

DAWN News on the Web

Why Day One Biopharmaceuticals, Inc.’s (DAWN) Stock Is Down 5.09%
AAII
Neutral
Why Day One Biopharmaceuticals, Inc.’s (DAWN) Stock Is Up 9.34%
AAII
Neutral
Why Day One Biopharmaceuticals, Inc.’s (DAWN) Stock Is Down 5.58%
AAII
Neutral
Why Day One Biopharmaceuticals, Inc.’s (DAWN) Stock Is Up 8.39%
AAII
Neutral
Why Day One Biopharmaceuticals, Inc.’s (DAWN) Stock Is Up 6.16%
AAII
Neutral
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade
Zacks
Bullish
Oppenheimer says Day One paying up to $285M for Mersana 'is interesting'
The Fly
Neutral
Day One’s Mersana Acquisition Puts Fast-Track Oncology Candidate Emi-Le in the Spotlight
Market Chameleon
Neutral

News Score - Last 7 Days

Neutral
DAWN
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DAWN’s Media Buzz Sentiment?
1 articles about DAWN were published this week. In an average week, 1.5 articles are published.
    What is DAWN’s weekly average amount of articles?
    In an average week, 1.5 articles about DAWN are published.
      What is DAWN’s News Sentiment?
      50% of articles about DAWN were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        XCURExicure
        SCLPScancell Holdings
        WVEWave Life Sciences
        STAAStaar Surgical
        DRTSAlpha Tau Medical Ltd
        Showing the stocks with the most bullish news sentiment over the past week